Investor Watchlist highlights key small-cap stocks facing growth challenges, with some firms showing improved profitability or cash generation, while others face risks like weak revenue, high costs, and cash burn.
FDA rejects UniQure's AMT-130 data, sending shares tumbling as the company scrambles to find a path to approval.
Colbert addresses 'reasonable' $16M settlement behind The Late Show's cancellation, citing network's financial decision amid difficult ad market.
Investor Watchlist highlights key small-cap stocks facing growth challenges, with some firms showing improved profitability or cash generation, while others face risks like weak revenue, high costs, and cash burn.
FDA rejects UniQure's AMT-130 data, sending shares tumbling as the company scrambles to find a path to approval.
Colbert addresses 'reasonable' $16M settlement behind The Late Show's cancellation, citing network's financial decision amid difficult ad market.